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The clinical comorbidity of alcohol dependence (AD) and
major depressive disorder (MDD) is well established,
whereas genetic factors influencing co-occurrence remain
unclear. A recent study using polygenic risk scores (PRS)
calculated based on the first-wave Psychiatric Genomics
Consortium MDD meta-analysis (PGC-MDD1) suggests a
modest shared genetic contribution to MDD and AD. Using a
(∼10 fold) larger discovery sample, we calculated PRS
based on the second wave (PGC-MDD2) of results, in a
severe AD case–control target sample. We found significant
associations between AD disease status and MDD-PRS
derived from both PGC-MDD2 (most informative
P-threshold= 1.0, P= 0.00063, R2= 0.533%) and PGC-
MDD1 (P-threshold= 0.2, P= 0.00014, R2= 0.663%) meta-
analyses; the larger discovery sample did not yield
additional predictive power. In contrast, calculating PRS in a
MDD target sample yielded increased power when using
PGC-MDD2 (P-threshold= 1.0, P= 0.000038, R2= 1.34%)
versus PGC-MDD1 (P-threshold= 1.0, P= 0.0013,
R2= 0.81%). Furthermore, when calculating PGC-MDD2
PRS in a subsample of patients with AD recruited explicitly
excluding comorbid MDD, significant associations were still
found (n= 331; P-threshold= 1.0, P= 0.042, R2= 0.398%).
Meanwhile, in the subset of patients in which MDD was not
the explicit exclusion criteria, PRS predicted more variance
(n= 999; P-threshold= 1.0, P= 0.0003, R2= 0.693%). Our
findings replicate the reported genetic overlap between AD
and MDD and also suggest the need for improved, rigorous
phenotyping to identify true shared cross-disorder genetic
factors. Larger target samples are needed to reduce
noise and take advantage of increasing discovery
sample size. Psychiatr Genet 28:66–70 Copyright © 2018
The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
The co-occurrence of alcohol dependence (AD) and
major depressive disorder (MDD) has been well estab-
lished, and epidemiological assessments of AD and
MDD have linked AD to higher risk of depression and
vice versa (Woodruff et al., 1973; Kessler et al., 1996;
Swendsen and Merikangas, 2000; Crum et al., 2008;
Foulds et al., 2015). Formal genetic studies indicate that
AD and MDD share common genetic factors (Winokur
and Coryell, 1991; Maier et al., 1994; Kendler et al., 1995;
Prescott et al., 2000; Nurnberger et al., 2002; Lyons et al.,
2006). Genome-wide association studies (GWAS) have
the ability to identify genetic loci associated with com-
plex disorders [e.g. AD (Treutlein et al., 2009; Kapoor
et al., 2014; Zuo et al., 2014; Gelernter et al., 2014) and
MDD (Ripke et al., 2013; Wray and Sullivan, 2017)] and
allow the study of genetic risk shared between complex
genetic disorders (Wray et al., 2014). So far, however, only
limited support for specific genes contributing to the two
illnesses on the level of individual genetic variation has
been found (Edwards et al., 2012).
The polygenic risk score (PRS) approach is a statistical
method that enables the assessment of additive effects of
multiple common genome-wide genetic variations on risk
for a disorder, and is well suited to characterize shared
genetic etiology of complex disorders (Purcell et al.,
2009). A recent study (Andersen et al., 2017) used this
approach to examine the genetic overlap between AD
and MDD. They calculated MDD-PRS based on the
results of the first-wave meta-analysis of the MDD
Working Group of the Psychiatric Genomics Consortium
(PGC) (PGC-MDD1: cases, n= 9240; controls, n= 9519)
GWAS (Ripke et al., 2013), finding associations with
increased risk for AD in four independent AD-GWAS
data sets (cases ranged from 317 to 2135), explaining from
0.18 to 2.6% of the variance in AD (Nagelkerke’s R2).
Mentioned as a limitation was the small size of the MDD
discovery sample used, proposing that increased sample
sizes would improve MDD-PRS predictive ability.
Here, we sought to substantiate the findings of Andersen
et al. (2017) in an independent sample of patients having
severe AD while calculating MDD-PRS based on the
much larger PGC-MDD2 discovery sample (n= 59 265
cases, n= 112 092 controls; Wray and Sullivan, 2017). For
context, we also calculated PRS using an MDD target
sample. Furthermore, we examined whether any asso-
ciation would be observed using a subset of this AD
sample whose patients had been recruited explicitly
excluding comorbid MDD.
Materials and methods
Target samples
The target sample comprised 1333 male patients with
German ancestry having severe AD requiring hospitali-
zation and 1307 population-based controls, previously
described in Treutlein et al. (2009) and Frank et al. (2012)
[i.e. the German Study on the Genetics of Addiction
(Alcoholism), GESGA]. Controls overlapping between
the GESGA sample and PGC-MDD discovery samples
were removed before analysis. In summary, all patients
fulfilled the AD DSM-IV criteria and were recruited from
consecutive admissions to psychiatry and addiction
medicine departments of psychiatric hospitals partici-
pating in the German addiction research network.
A subset of the cases (PREDICT subsample; Mann et al.,
2009) comprising 332 patients with AD was recruited
explicitly excluding comorbid MDD.
The MDD target sample comprised cases (n= 597) from
the Bonn/Mannheim (BoMa) MDD study and German
population-based controls (n= 1292), described pre-
viously (Rietschel et al., 2010; Ripke et al., 2013).
All participants provided written informed consent, and
procedures used were approved by the respective local
ethics committees and in accordance with the
Declaration of Helsinki.
Discovery samples
The PGC-MDD2 discovery sample comprised 59 265
cases and 112 092 controls (leave-one-out meta-analysis
omitting the BoMa-MDD sample included in the original
PGC-MDD2 (Wray and Sullivan, 2017) meta-analysis).
The PGC-MDD1 discovery sample comprised 8148
cases and 7955 controls (leave-one-out meta-analysis
omitting the BoMa-MDD and RADIANT-German
samples included in the original PGC-MDD1 (Ripke
et al., 2013) meta-analysis which had overlapping controls
with the GESGA sample). The PGC-MDD1 data set is a
subset of the PGC-MDD2 data set.
Genotyping and quality control
Detailed information on genotyping and QC is available in
Frank et al. (2012). In summary, filtering for uncommon
SNPs (minor allele frequency< 0.1), individual missing-
ness (>0.01), low-quality genotyping (missingness > 0.02),
and Hardy–Weinberg equilibrium (1.0× 10-6) was per-
formed. After QC and excluding overlapping samples, the
final GESGA sample comprised 1330 cases and 1051
controls (n= 382001 SNPs). Of these cases, 331 were from
the PREDICT study and 999 were not. Additional minor
allele frequency filtering was performed for each sub-
sample (PREDICT: n= 381453 SNPs; non-PREDICT:
n= 381914 SNPs). After QC and removing overlap, the
BoMa-MDD sample comprised 586 cases and 1062 con-
trols (n= 3523389 SNPs).
Polygenic risk score calculation
PRSs were calculated using PRSice v1.25 (Euesden et al.,
2015). We calculated MDD-PRS in the GESGA sample
using the PGC-MDD2 results following previously
published methods (Ripke et al., 2014).
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In summary, linkage disequilibrium (LD) clumping was
carried out, retaining the variant with the smallest P value
from each LD block and discarding all variants with r2
greater than or equal to 0.1 located within 500 kb around
that variant. The major histocompatibility complex of
chromosome 6 was excluded, as frequently done when
calculating PRS owing to long-range LD, making linkage
equilibrium difficult to contain (Euesden et al., 2015).
PRS were calculated at a range of P value thresholds
(P= 5× 10− 8, 1× 10− 6, 1× 10− 4, 0.001, 0.01, 0.05, 0.1,
0.2, 0.5, 1.0).
Regression analyses were performed on AD case–control
status with the first 10 principal components as covari-
ates. The proportion of variance in case–control status
explained by MDD-PRS was assessed by Nagelkerke’s
pseudo R2 derived from the difference between the full
regression model (PRS+ covariates) and the null model
(only covariates) (Purcell et al., 2009; Power et al., 2015).
For comparison, we calculated MDD-PRS in the GESGA
sample using the PGC-MDD1 discovery sample.
For context, we further analyzed the association of the
MDD-PRS with MDD phenotype using the same para-
meters in the BoMa-MDD target sample, using both
PGC-MDD1 and PGC-MDD2 results, serving as a
positive control.
To examine whether existing AD/MDD comorbidity
might be driving association, we conducted several
additional analyses. Using the PGC-MDD2 results as the
discovery sample, we analyzed PRS separately in
PREDICT subsample cases (n= 331) and non-PREDICT
cases (n= 999).
Results
Tables S1-3 show P value thresholds, significance (P
values), R2, and number of informative SNPs, which were
included at each P value threshold for each PRS analysis.
We found significant associations between AD disease sta-
tus and MDD-PRS derived from both PGC-MDD2 (most
informative P-threshold=1.0, P=0.00063, R2=0.533%;
Fig. 1a) and PGC-MDD1 (P-threshold=0.2, P=0.00014,
R2=0.663%; Fig. 1b) meta-analyses; the larger discovery
sample did not yield additional predictive power.
In contrast, calculating PRS in a MDD target sample yielded
increased power when using PGC-MDD2 (P-threshold=1.0,
P=0.000038, R2=1.34%; Fig. 1c) versus PGC-MDD1
(P-threshold=1.0, P=0.0013, R2=0.81%; Fig. 1d).
When calculating PGC-MDD2 PRS in the PREDICT
subsample (excluding comorbid MDD), significant
associations were still found (P-threshold= 1.0, P= 0.042,
R2= 0.398%). Meanwhile, PRS in non-PREDICT cases
(i.e. not explicitly excluding MDD comorbidity) pre-
dicted more variance (P-threshold= 1.0, P= 0.0003,
R2= 0.693%; Fig. 1e, inset).
Discussion
Our analysis confirms the contribution of shared genetic
risk for AD and MDD long suggested by formal genetics
studies that was only recently detected using a molecular
approach in Andersen et al. (2017).
Determining shared genetic etiology in comorbid dis-
orders is necessarily faced with the problem of ‘enrich-
ment’ of the comorbid disorders in both discovery and
target samples. Our analysis of the PREDICT sample
alone revealed that even in AD cases expressly excluding
comorbid MDD, genetic overlap is observed; a higher
proportion of explained variance was observed using only
non-PREDICT cases. These findings are consistent with
those of Andersen et al. (2017), who showed that sig-
nificant genetic overlap remained when calculating PRS
in the AD-GWAS data sets after adjusting for MDD
status, and also when using a MDD GWAS data set
without comorbid MDD-AD cases (Andersen et al.,
2017). These results suggest that although PGC-MDD-
GWAS samples are likely to contain individuals with AD,
these are not fully responsible for the associations
observed. For our current analysis, comorbidity informa-
tion with AD in the PGC-MDD2 discovery sample was
not available, nor was MDD status in the full GESGA
sample; it should be noted that the possibility of
enrichment nevertheless remains. Moreover, these find-
ings underscore the need for rigorous phenotyping and
improved characterization of samples, and in particular
detailed assessment of disease comorbidity, symptoma-
tology, and severity, all of which will be vital in the effort
to understand shared genetic risk of complex diseases.
Interestingly, our use of a substantially larger discovery
sample did not demonstrate increased predictive power
in the AD sample. One reason for this is that the effect
itself is modest in size and less robust against noise. In
contrast, the larger discovery sample did yield increased
predictive power in the MDD sample; the effects were
much stronger. One consideration with respect to our
findings is that patients in our AD sample were all males,
whereas the discovery sample in addition contained
females, potentially affecting predictability. Meanwhile,
the MDD target sample contained both males and
female patients. However, additional analysis using male-
only MDD-PRS, and statistically controlling for sex in
the MDD-BoMa samples, did not indicate a substantial
influence of sex on our results (see Supplementary
Material, Supplemental digital content 1, http://links.lww.
com/PG/A204).
Another recent study using a polygenic approach has
shown that the level and risk of AD and MDD comor-
bidity may be linked to neuropsychiatric traits and brain
volumes (Zhou et al., 2017). Further research is needed to
decipher this pleiotropy and to assess causality. Although
not possible here owing to the relatively small size of the
target sample, the application of techniques to dissect
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pleiotropy, such as BUHMBOX (Han et al., 2016) or
Mendelian randomization (Davey Smith and Hemani,
2014), will lead to better understanding of this disease
comorbidity. Another approach which can be utilized
with larger target samples is LD score regression to
estimate genetic correlation across diseases and sub-
groups (Bulik-Sullivan et al., 2015).
Ongoing increases in discovery sample size will lead to
continued increases in the ability to explain variance in
mental disorders, augmenting the ability to further dis-
sect the shared pathophysiology reflected in the genetic
overlap between comorbid diseases. Larger target sam-
ples are needed to reduce noise and take advantage of
increasing discovery sample size.
Our findings replicate the genetic overlap between AD
and MDD and suggest the need for improved, rigorous
phenotyping to identify true shared cross-disorder
genetic factors. Once assessed, future efforts in the
field will be able to take advantage of symptomatology
and precise comorbidity information to inform analyses.
Importantly, this will also lead to both improved patient
stratification and corresponding personalization of care in
clinical settings.
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